Skip to main content
. 2021 Jul 9;61(4):1589–1599. doi: 10.1093/rheumatology/keab522

Fig. 1.


Fig. 1

Flowchart for analytic approach

Data are n. bDMARD: biological disease-modifying antirheumatic drugs; CVD: cardiovascular disease; MACE: major adverse cardiac event.